ArticleWorld journal of surgical oncology2025
Clinical significance of preoperative serum VEGF in predicting metachronous liver metastasis of colorectal cancer: development of a novel nomogram.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetachronous liver metastasis (MLM) after primary resection of colorectal cancer (CRC) substantially worsens patient prognosis. Vascular endothelial growth factor (VEGF) is a highly bioactive proangiogenic protein. However, few studies have used serum VEGF to predict CRC liver metastasis, particularly MLM. This study investigated the predictive value of preoperative serum VEGF levels for the development of MLM in patients with CRC and developed a novel nomogram.
methodsData from 229 patients with CRC who underwent radical resection of the primary tumor at the First Affiliated Hospital of Henan University between June 2019 and June 2022 were retrospectively analyzed. Patients were divided into training (n = 153) and validation (n = 76) cohorts. Independent risk factors for MLM were identified in the training cohort and were used to develop and validate the nomogram.
resultsPreoperative VEGF levels > 436.81 pg/mL, preoperative carcinoembryonic antigen levels > 5.0 ng/mL, T stage, N stage, and mismatch repair proficiency were independent risk factors for MLM and were used to develop the nomogram. The concordance index of the training cohort was 0.849 (95% confidence interval: 0.765–0.933). Calibration curve analysis revealed that the standard curve fit well with the predicted curve. Receiver operating characteristic curve analysis demonstrated the nomogram’s high efficiency. Decision curve analysis confirmed the nomogram’s significant clinical value.
conclusionWe developed a novel nomogram including VEGF and mismatch repair proficiency in this study which were rarely reported in previous studies and the novel nomogram exhibits good discriminative ability and high accuracy in predicting MLM in patients with CRC. The identification of patients at a high risk of MLM would enable closer monitoring and timely interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.